基因治疗公司Adverum(ADVM.US)盘前跳涨！获礼来(LLY.US)收购要约

智通财经2025-10-24

智通财经APP获悉，制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振，Adverum周五美股盘前一度涨近29%，截至发稿涨幅缩窄至逾6%。根据协议，礼来将发起收购要约，以每股3.56美元的价格收购所有已发行的Adverum股票。该协议还附带一项或有价值权(CVR)，若满足...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2577511046?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-24 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577511046","market":"sh","top_or_hot":-1,"title":"基因治疗公司Adverum(ADVM.US)盘前跳涨！获礼来(LLY.US)收购要约","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振，Adverum周五美股盘前一度涨近29%，截至发稿涨幅缩窄至逾6%。根据协议，礼来将发起收购要约，以每股3.56美元的价格收购所有已发行的Adverum股票。该协议还附带一项或有价值权(CVR)，若满足...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1359687.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>基因治疗公司Adverum(ADVM.US)盘前跳涨！获礼来(LLY.US)收购要约</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n基因治疗公司Adverum(ADVM.US)盘前跳涨！获礼来(LLY.US)收购要约\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-24 21:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1359687.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振，Adverum周五美股盘前一度涨近29%，截至发稿涨幅缩窄至逾6%。根据协议，礼来将发起收购要约，以每股3.56美元的价格收购所有已发行的Adverum股票。该协议还附带一项或有价值权(CVR)，若满足...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1359687.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836757.USD","symbol_name":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1359687.html","article_id":"2577511046","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577511046","pubTimestamp":1761312180,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，制药巨头礼来周五公布了收购基因治疗公司Adverum Biotechnologies及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振，Adverum周五美股盘前一度涨近29%，截至发稿涨幅缩窄至逾6%。根据协议，礼来将发起收购要约，以每股3.56美元的价格收购所有已发行的Adverum股票。礼来表示，此次收购将结合其基因药物研发能力与Adverum在眼科基因疗法领域的技术优势，有助于拓展基因疗法在减轻年龄相关疾病负担方面的潜力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","ADVM":"Adverum Biotechnologies, Inc.","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LLY":"礼来","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","BK4599":"减肥药","LU1548497426.USD":"安联环球人工智能AT Acc","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC"},"translate_title":"Gene therapy company Adverum (ADVM.US) jumped before the market! Received an acquisition offer from Eli Lilly (LLY.US)","themeId":"0de6a0a50611a781da668f8b53e018c2","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1.5,"ADVM":1.5},"content_text":"智通财经APP获悉，制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振，Adverum周五美股盘前一度涨近29%，截至发稿涨幅缩窄至逾6%。根据协议，礼来将发起收购要约，以每股3.56美元的价格收购所有已发行的Adverum股票。该协议还附带一项或有价值权(CVR)，若满足特定里程碑条件，每股可额外获得最高8.91美元，使交易总潜在价值达到每股12.47美元。据悉，Adverum专注于开发玻璃体腔内单次给药基因疗法，旨在研发可恢复视力、防止失明的功能性治愈方案。其核心产品候选药物Ixo-vec是一种用于治疗湿性老年黄斑变性(wAMD)的玻璃体腔内基因疗法。礼来表示，此次收购将结合其基因药物研发能力与Adverum在眼科基因疗法领域的技术优势，有助于拓展基因疗法在减轻年龄相关疾病负担方面的潜力。该交易预计将在2025年第四季度完成，需满足惯常的交割条件。此外，若要约收购成功完成，礼来将通过第二步合并(second-step merger)收购所有未在要约中被涉及的Adverum股份，收购价格与要约条件一致。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577511046","isCrawlerRequest":true}